On April 21^st 2025, Guo Lab at Shenzhen Bay Laboratory (SZBL) convened an internal Alzheimer’s disease (AD) symposium themed “Diagnostic and Therapeutic Targets for Alzheimer’s Disease in APOE4 Carriers”. The full-day meeting was held at SZBL Building B, Room 103        

        Organized by Dr. Tengfei Guo, the symposium focused on advancing mechanistic understanding and translational strategies for AD in the context of the APOE4 risk genotype, including discussions on disease mechanisms, newly target discovery, and early-stage clinical prospects. 

        The agenda of the symposium featured a series of research presentations spanning cohorts, molecular imaging, genetics, and human cellular models, including:

• 1. Opening remarks by Dr. Tengfei Guo (Shenzhen Bay Laboratory). 

• 2. Research on how prodromal psychobehavioral changes may progress to AD (Shanghai Mental Health Center; Dr. Xia Li). 
• 3. Updates on the CPAS molecular imaging cohort for preclinical AD research (Huashan Hospital, Fudan University; Dr. Fang Xie). 
• 4. Findings from human and macaque cohorts identifying synergistic and antagonistic factors associated with APOE4 (Kunming Institute of Zoology, Chinese Academy of Sciences; Dr. Dengfeng Zhang). 
• 5. Applications of human iPSC-derived differentiation models in studying APOE-regulated AD pathology (Suzhou University; Dr. Jing Zhao). 
• 6. A progress report on the “FAITH” cohort (Fujian Medical University; Dr. Jiawei Xin). 

• 7. Updates on the “Greater-Bay-Area Healthy Aging Brain Study (GHABS) cohort”, including community-based AD cohorts and APOE4 early diagnosis and intervention (Shenzhen Bay Laboratory; Dr. Tengfei Guo).

        The symposium concluded with an extended post-meeting discussion session to facilitate in-depth scientific exchange and explore future collaboration opportunities. 

        By bringing together multi-institutional expertise across clinical cohorts, imaging, genetics, and stem-cell modeling, the symposium strengthened cross-disciplinary dialogue toward more precise and actionable strategies for Alzheimer’s disease—particularly for individuals carrying the APOE4 risk allele.